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Rai stageAbstract Background: B-cell chronic lymphocytic leukemia (CLL) is marked by the accumulation
of CD5+ B lymphocytes within the blood, bone marrow (BM), and secondary lymphoid tissues.
Abnormalities in the expression and function of cell adhesion molecules may account for the pat-
terns of intra-nodal growth and hematogenous spread of the malignant cells. Chemokines and
integrin-mediated adhesion and trans-endothelial migration (TEM) are central aspects in trafficking
and retention of hematopoietic cells in the BM and lymphoid organs.
Aim of the work: This work was conducted to study adhesion molecules status in CLL and its
potential impact on both hematological and clinical parameters.
Patients and methods: The study included 78 newly diagnosed CLL patients. Immunophenotyping
was performed on peripheral blood using the chronic lymphoid panel. Adhesion molecules (CD11a,
CD11b, CD49d, CD49C, CD29 and CD38) were tested using monoclonal antibodies and analyzed
by Flow Cytometry.
Results: Positive correlation was encountered between adhesion molecules: CD38 with CD49d
(r= 0.25, p= 0.028), CD11a with CD11b, CD49d and CD29 (r= 0.394, p= 0.001; r= 0.441,
p=<0.01 and r= 0.446, p< 0.01 respectively) and CD29 with CD49c and CD49d (r= 0.437,
p< 0.01; r= 0.674, p< 0.01 respectively).
CD49c showed negative correlation with Rai staging (r= 0.269, p= 0.033). CD11a and CD29
showed a significant relation with splenomegaly (p= 0.04 and 0.03 respectively) and CD49d
showed a significant relation with lymphadenopathy (p= 0.02).
Conclusion: The level of different adhesion molecules expression in CLL is apparently reflected on
the potential migratory behavior of the leukemic cells to different organs.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).oo.com
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CLL is a malignant disease of B-cells with characteristic phe-
notype. In USA, it accounts for 4.5%/100,000 person per
year [1]. In Egypt, according to NCI hospital-based registry
(2002–2010), CLL accounts for 0.5% of all cancers and
3.08% of lymphohemopoietic malignancies. Most cases do
not entail treatment until evident progression of disease is
encountered [2]. Mere staging by Binet [3] or Rai [4] is not sat-
isfactory to expect which clinical course the patient will expe-
rience. Numerous, more recently suggested, markers
apparently contribute to the cellular processes involved in
CLL pathogenesis [5]. Chemokine and integrin-mediated adhe-
sion and trans-endothelial migration (TEM) are central aspects
in trafficking and retention of hematopoietic cells in the BM
and lymphoid organs. To enter these organs, circulating cells
need to arrest on specific endothelial barriers, to locomote over
the endothelial surface toward inter-endothelial junctions, and
to cross these junctions while resisting disruptive shear forces
[6]. Both firm adhesion and ability to locomote and transmi-
grate across endothelial barriers depend on the ability of circu-
lating cells to establish dynamic adhesive interactions through
VLA-4 and LFA-1 integrins. During these interactions, the
integrins undergo reversible activation by endothelial-
presented chemokines [7]. From this prospect, many adhesion
molecules have been linked to natural history of CLL, the pat-
tern of organ and bone marrow invasion as well as various
hematological and clinical parameters.
In this work, we have studied a number of adhesion mole-
cules (CD11a, CD11b, CD49c, CD49d, CD29 and CD38) in a
cohort of newly diagnosed CLL patients. We aimed to deter-
mine the level of expression of these markers in CLL patients
and to verify their impact on clinical and hematological
parameters.Material and methods
Patients
The study was conducted on 78 newly diagnosed CLL patients
attending at the National Cancer Institute, Cairo University,
during the period from March 2013 to December 2014.
Patients were selected on the basis of standard clinical, hema-
tological and immunophenotypic criteria. They included 52
males and 26 females; their age ranged from 25 to 85 with a
mean of 59.58 ± 10.98 and a median of 60 years.
Methods
All patients were subjected to history taking and clinical exam-
ination stressing on the presence of lymphadenopathy, spleno-
megaly, hepatomegaly, and symptoms and signs of anemia
and/or thrombocytopenia. Imaging studies were performed
for assessing organomegaly. Laboratory investigations
included complete blood count (CBC) using Cell Dyn 37000,
Leishman-stained peripheral blood (PB) smear examination,
laying stress on lymphocyte percentage and absolute lympho-
cyte count. Bone marrow (BM) aspiration with examination
of Leishman-stained smears for lymphocyte percentage and
morphology. The work was conducted according to Helsinkideclaration for studies involving human beings. It was
approved by the IRB of the NCI, Cairo University and
exempted from obtaining patient’s consent. The study was per-
formed at the Bone Marrow Transplantation Laboratory Unit
(BMT Lab Unit), NCI, Cairo University.
Clinical data were available for 67 and hematological data
for 69 patients.
Flow Cytometry analysis
Immunophenotyping was performed on peripheral blood.
Chronic lymphoproliferative panel was applied. It includes
CD5, CD19, CD20, CD22, CD23, CD79b, FMC7, CD10,
CD11C, CD103, CD25, CD123, CD3, CD4, CD8, CD16,
CD56, Cyclin D1, IgM, CD2, CD7 as well as j and k light
chains; all were purchased from Beckman Coulter. Additional
adhesion molecule panel was used including CD38 (T16) phy-
coerythrin (PE), CD11b (Bear 1) PE, CD49d (HP211) fluo-
rescin isothiocyanate (FITC) and CD29 (K20) FITC were
supplied from Beckman Coulter; CD11a (HI 111) FITC and
CD49c (ASC-1) PE were obtained from Biolegend (San Diego,
CA, USA). Whole blood staining method was applied as pre-
viously described. Twenty microliter labeled Mo Ab were dis-
pensed into appropriately labeled tubes. One hundred-
microliter sample was added and incubated in the dark for
20 min. Three and half milliliter lysing reagent was added to
each tube, inverted once and kept for 5 min. Centrifugation
at 1500g (3200 rpm) for 3 min was done, 3.5 ml PBS added,
and centrifugation at 1500g (3200 rpm) for 3 min repeated.
Samples were suspended in PBS, tubes vortexed and analyzed
using a Coulter Epics XL Hilah Flow Cytometer.
The instrument set up was checked daily using QC check
beads Flow Cytometry purchased from Beckman Coulter
(Miami, USA). Forward scatter and side scatter measurements
were made using linear amplifiers, while mean fluorescence
measurements were made with logarithmic amplifiers. Flow
cytometric two-parameter dot plots and quadrant statistics
were generated. A region around the lymphocyte population
on a forward scatter versus side scatter dot-plot was created
manually. A second gate was subsequently put on the CD19
positive B-lymphocyte population.
A marker was considered positive at a cutoff of 20%.
Statistical analysis
Statistical package for Social Science (SPSS 15.0.1 for win-
dows; SPSS Inc, Chicago, IL, 2001) was used for data manage-
ment and analysis. Mean and Standard deviation described
quantitative data with median and range when appropriate.
Number and percentage described qualitative data. Chi-
square and Fisher exact tested proportion independence. p
value was set significant at 0.05 level. Correlation analysis
(using Pearson’s method) was used to assess the strength of
association between two quantitative variables. The correla-
tion coefficient denoted symbolically ‘‘r” defines the strength
and direction of the linear relationship between two variables.
Results
The study was performed on 78 CLL patients including 52
(66.67%) males and 26 (33.33%) females; their age ranged
Adhesion molecules in CLL 33from 25 to 85 with a mean of 59.58 ± 10.98 and a median of
60 years. Clinical and hematological parameters are presented
in (Tables 1 and 2). Using the scoring system, the majority of
our cases had a score of 5 (50/78, 64.1%) and 4 (21/78, 26.9%);
only 7/78 (9%) had a score of 3.
In our study, Rai staging was distributed as follows: 1 case
(1.4%) stage 0, 14 (20.3%) stage I, 21(30.4%) stage II, 24
(34.8%) stage III, 9 (13%) stage IV.
Adhesion molecules expression
The frequency and percentage expression of the various adhe-
sion molecules are presented in (Table 3).
The adhesion molecules showed marked variability in their
expression, the most frequent was CD49d followed by CD29,
CD38, both CD49c and CD11a and the least was CD11b
expressed on two cases (2.56%) only. Also there was marked
variability in percentage expression in positive cases from just
achieving the cutoff up to expression on more than 90% of the
cells.Table 1 Clinical findings in 67 chronic lymphocytic leukemia
(CLL) patients.
Parameter CLL
Age: mean ± SD 59.58 ± 10.98
Median (range) 60 (25.00–85.00)
Gender: No (%)
Male 52 (66.67%)
Female 26 (33.33%)
Hepatomegaly: No (%) 33/67 (49.30%)
Splenomegaly: No (%) 43/67 (64.20%)
Lymphadenopathy: No (%) 56/67 (83.60%)
Table 2 Hematological findings in 69 chronic lymphocytic leukemi
Parameter Mean ± SD
Median (range)
Total leukocyte count  109/L 113.57 ± 131.93
71.37 (4.90–567.00)
Hemoglobin: gm/dL 10.65 ± 2.78
11.1 (4.20–15.80)
Platelets  109/L 188.54 ± 118.79
172.00 (17.00–846.00)
Lymphocyte% 81.55 ± 15.89
88 (44–99)
Table 3 Expression of adhesion molecules on 78 chronic lymphocy
Adhesion molecule Frequency No (%)
M
CD49d 27/78 (34.61%) 6
CD49c 15/78 (19.23%) 6
CD11a 14/78 (17.95%) 4
CD11b 2/78 (2.56%) 3
CD29 23/78 (29.49%) 5
CD 38 19/78 (24.36%) 5
a Actual values for the 2 cases.Correlation between adhesion molecules with each other as
well as with prognostic hematological parameters and Rai
stage are presented in (Table 4).
In our study Rai staging showed a positive correlation with
ALC (r= 0.438, p=<0.01) and a negative correlation with
Hb level (r= 0.766, p=<0.01) and CD49c (r= 0.269,
p= 0.033).
CD11a showed a positive correlation with CD11b
(r= 0.394, p= 0.001), CD49d (r= 0.441, p=<0.01) and
CD29 (r= 0.446, p=<0.01) (Fig. 1). CD29 showed a posi-
tive correlation with CD49d (r= 0.674, P=<0.01), CD49c
(r= 0.437, P=<0.01) and CD11a (r= 0.446, P=<0.01)
(Fig. 2). D38 showed a positive correlation with CD49d
(r= 0.250, P= 0.028) (Fig. 3).
Splenomegaly showed a significant relation with CD11a
(P= 0.04) and CD29 (P= 0.03). Lymphadenopathy showed
a significant relation with CD49d (P= 0.02).
Discussion
Extreme clinical heterogeneity is one of the hallmark features
of CLL. Despite the identification of genetic and phenotypic
markers that correlate with prognosis, the biological basis of
this clinical variability remains unclear. Progressive CLL is
defined by the expansion of the neoplastic clone and extravas-
cular accumulation in lymphoid tissues, bone marrow and
other organs.
Infiltration at these sites gives rise to the characteristic clin-
ical picture of immune dysfunction, lymphadenopathy, spleno-
megaly and hematopoietic failure; features that correlate with
survival [3,4].
Adhesion molecules are a group of ligands and receptors
involved in several biological processes, particularly cell migra-a patients.
Parameter Mean ± SD
Median (range)
Absolute lymphocyte count  109/L 103.17 ± 126.30
66.37(3.19–561.30)
B.M cellularity:
Normocellular 21/61 (34.40%)
Hypocellular 2/61 (3.30%)
Hypercellular 38/61 (62.30%)
Bone marrow lymphocyte% 71.00 ± 20.15
72.00 (18.00–98.00)
tic leukemia patients.
Expression in positive cases
ean ± SD Median Range
1.9 ± 23.41 63.90 22.50–94.70
2.43 ± 21.75 64.00 26.50–96.00
3.99 ± 17.72 36.50 20.40–74.40
7.90 and 71.00a 54.45 37.90–71.00
9.41 ± 19.56 59.00 23.40–89.30
6.62 ± 18.70 53.50 32.00–82.00
Table 4 Correlation matrix for different adhesion molecules in 78 chronic lymphocytic leukemia patients.
Parameter Hemoglobin Platelets ALC Rai stage CD49d CD49c CD11a CD11b CD29
Plateletsa r 0.053
p 0.665
ALCa r 0.632 0.175
p 0.000 0.150
Rai stagea r 0.766 0.198 0.438
p 0.000 0.103 0.000
CD49d r 0.005 0.107 0.166 0.006
p 0.965 0.382 0.173 0.964
CD49c r 0.203 0.003 0.202 0.269 0.167
p 0.111 0.984 0.111 0.033 0.165
CD11a r 0.130 0.050 0.064 0.137 0.441 0.101
p 0.305 0.696 0.616 0.279 0.000 0.407
CD11b r 0.079 0.010 0.106 0.093 0.107 0.138 0.394
p 0.528 0.939 0.398 0.455 0.363 0.251 0.001
CD29 r 0.002 0.009 0.178 0.009 0.674 0.437 0.446 0.170
p 0.987 0.944 0.143 0.941 0.000 0.000 0.000 0.144
CD38 r 0.081 0.079 0.064 0.097 0.250 0.085 0.033 0.024 0.213
p 0.506 0.517 0.602 0.430 0.028 0.479 0.784 0.841 0.061
ALC: absolute lymphocytic count, bold font denotes significance.
a For platelets, ALC and Rai staging, correlations were done for 69 cases only.
34 A.M. Kamel et al.tion [8]. Given that some B-NHL subtypes are considered to be
the malignant counterparts of distinctive steps in normal B-cell
development, it is reasonable to infer that the malignant lym-
phoid cells use the same mechanisms of lymphocyte migration
as normal B cells to disseminate from their primary sites. In
fact, a number of in vitro [9] and preclinical experiments
[10], as well as clinical observations [11] give support to this
hypothesis. Matos et al. [12] studied the expression of 10 adhe-
sion molecules in tumor cells from the peripheral blood of
patients with leukemic B-NHL (chronic lymphocytic leukemia,
mantle-cell lymphoma, nodal or splenic marginal B-cell lym-
phoma) to determine how the down-regulation of specific
adhesion markers inherently associated with malignant trans-
formation contributes to the biogenesis of the leukemic phase
observed in some B-NHL subtypes.Figure 1 (A) Correlation between CD49c and Rai staging in 67. (B) C
leukemia patients.In our study Rai staging showed a positive correlation with
ALC and a negative correlation with Hb level; this is expected
as ALC and Hb level contribute to Rai staging. A negative cor-
relation was also encountered with CD49c; this negative corre-
lation is in harmony with the previously addressed good
prognostic value of CD49c [13].
In our series, CD29 showed a positive correlation with
CD49d and CD49c; this is because CD29 is the common b1
chain of a subunits of integrins a3/CD49c and a4/CD49d
[8,12].
A positive correlation was also encountered between
CD11a with CD11b, CD49d and CD29. This positive correla-
tion might reflect the contribution of more than one adhesion
molecule to the trafficking and infiltrating pattern of the
malignant cells. It has to be noted that only two cases wereorrelation between CD49d and CD11a in 78 chronic lymphocytic
Figure 2 CD29 correlations in 78 chronic lymphocytic leukemia patients (A) with CD49c, (B) with CD49d, (C) with CD11a.
Figure 3 CD49d correlations with CD38 in 78 chronic lympho-
cytic leukemia patients.
Adhesion molecules in CLL 35considered positive for CD11B expression (P20%). However
the direct correlation involves the true% expression regardless
if the case is considered positive (P20%) or not and it could
still be meaningful. CD11a and CD49d were both reported
to have lower expression in chronic lymphocytic leukemia
[12] suggesting that these adhesion molecules are probably
responsible for the different compartments the disease infil-
trates compared to its related entity, the small lymphocytic
lymphoma. It was suggested that the higher frequency of blood
invasion by tumor cells in CLL, when compared with the other
B-NHL, could be explained by specific profiles of adhesion
molecule expression. Since the structure of normal lymphoid
follicles in lymph nodes depends on the appropriate associa-
tion between B lymphocytes and dendritic follicular cells
through the interaction of CD11a and ICAM-1 (an intercellu-
lar adhesion molecule), and of CD49d and VCAM1 (a vascu-
lar cell adhesion molecule) respectively [14], the lower
expression of CD11a and CD49d on tumor cells of CLL could
facilitate their detachment from the lymph node, while the
expression of these adhesion molecules is preserved in small
36 A.M. Kamel et al.lymphocytic lymphoma [15]. In fact, the down-regulation of
CD11a and CD49d in chronic lymphocytic leukemia could
also explain the peripheral blood invasion by these malignant
cells, as compared with the occasional infiltration observed in
mantle-cell lymphoma and marginal B-cell lymphoma [12]. It
is worth mentioning that we observed a trend for higher
CD49d values in MCL than in CLL (P= 0.06) [unpublished
data].
In the current study, splenomegaly showed a significant
relation with CD11a and CD29. Hartmann et al. [16] found
that CLL samples expressed markedly reduced LFA-1 levels
and failed to home to LNs but exhibited spleen tropism. Lym-
phocyte spleen homing does not necessarily require integrin
activation [17], also they observed that CLL cases with high
LFA-1 expression and trans-migratory capacity can enter
LNs at low numbers.
In this study, we found significant relation between lym-
phadenopathy and CD49d. This is consistent with other stud-
ies that linked CD49d to the presence of bulky
lymphadenopathy and/or adverse outcome in CLL [18,19].
In addition to their role in tissue invasion, interactions
between VLA4 and its ligand VCAM1 have been shown to
promote the viability of CLL cells and high levels of CD49d
were associated with increased numbers of VCAM1 expressing
micro-vessels within lymph nodes [20].
The combination of a strong expression of CD49c and a
weak expression of CD49d is the hallmark of chronic lympho-
cytic leukemia and can be used to differentiate this disease
from other B-NHL in leukemic phase. It has been shown that
imbalance in CD49c/CD49d expression in chronic lymphocytic
leukemia contributes to the peripheral blood invasion [21].
Moreover, other studies have demonstrated prognostic rele-
vance of the combination of high CD49c and low CD49d
expression in chronic lymphocytic leukemia [22].
Our results revealed a positive correlation between CD38
and CD49d; this is in agreement with other studies [16,23,24].
Zucchetto et al. [24] observed statistically significant correla-
tion between CD49d and CD38 (r = 0.59, p= 60.001); lower
but still significant associations were found between CD49d
expression and Rai staging.
Hartmann et al. [16] observed a highly significant higher
VLA-4 expression in CD38 high-risk groups compared with
CD38 low risk groups with nearly total loss of VLA-4 in the
low-risk group. The low expression of both VLA-4 and
LFA-1 in low-risk CLL groups might explain the more favor-
able clinical course of these patients because it obviously
restricts circulating CLL cells from re-entering the BM and
from homing to the LNs and other organs where these cells
are likely to encounter anti-apoptotic factors. Simultaneous
over expression of CD38 and CD49d was claimed to be a part
of the signature characterizing the CLL subgroup with the
worst outcome [22,24].
The migration of lymphocytes into tissues is initiated by
chemokine-induced activation of integrins, which increases
their affinity for endothelial ligands such as intercellular adhe-
sion molecule 1 (ICAM1) and vascular cell adhesion molecule
1 (VCAM1) [25]. This results in firm adhesion and migration
though the endothelial barrier. In some cells integrins are
arranged in supra-molecular complexes termed podosomes
[26] that are linked to the cytoskeleton and contain other
proteins involved in tissue invasion such as matrixmetalloproteinases. Other studies suggested that CLL cells,
but not normal B cells, possess podosomes containing a4b1
integrin (VLA4) [27].
These observations are paralleled by the work of Patten
group [28] showing that CD38-positive cases of CLL have
increased numbers of micro-vessels in lymph nodes and Bug-
gins et al. study [29] in which interactions with vascular
endothelial cells were shown to inhibit CLL cell apoptosis
through nuclear factor NFKB-mediated regulation of Bcl-2
family proteins.
Comparing the integrin expression on CD38 high and low
CLL cells, Pittner et al. [30] found an increased VLA-4
(CD49d subunit) and LFA-1 (CD18 subunit) expression in
the CD38 high subtype, making it difficult to ascribe enhanced
migration functions solely to CD38.
A number of molecules involved in migration through
endothelium and tissue invasion have also been correlated with
disease progression in CLL including CCR7, CD49d and
matrix metalloproteinase 9 (MMP-9) [19]. In addition, the
membrane of CLL cells has been shown to contain a supra-
molecular complex involved in tissue migration and
metastasis.
A possible molecular basis for the high correlation of
CD49d and CD38 expression in CLL could be their physical
association in multi-protein-complexes. Buggins et al. [23]
reported a multimer-complex involving CD38, CD49d,
MMP9, and CD44 and observed a co-immunoprecipitation
of CD38 with CD49d in the majority.
CD38/CD49d/MMP9/CD44 complex plays a role in migra-
tion into the tissues and in pro-survival signaling. Accumula-
tion of leukemic cells in the tissues is responsible for many
of the clinical features of CLL and defines a more advanced
and progressive disease with an adverse outcome [3,4]. Tissue
invasion also exposes the tumor cells to other components of
the leukemic microenvironment such as T cells, nurse-like cells
and other stromal elements that promote expansion of the leu-
kemic clone [28,29].
The identification of the CD38/CD49d complex thus sug-
gests a biological basis for the correlation between the expres-
sion of these molecules and prognosis. As the structure is not
present in normal B cells, it also presents a novel leukemia-
specific target for the therapy of this common disorder.
These structures contain CD49d, CD44 and MMP-9 and
are not present in normal B cells [27]. Given the clinical corre-
lation noted between CD38 and CD49d expressions in CLL
[19,30] and the known involvement of both in tissue migration,
Buggins et al. [23] hypothesized that CD38 might be physically
associated with CD49d as part of this supramolecular complex
in CLL cells.
In conclusion our results demonstrated the extreme vari-
ability in the level of expression of various adhesion molecules
on CLL cells. The expression level of the adhesion molecules
(CD38, CD11a, CD11b, CD49C and CD49d) might be
reflected on the pattern of trafficking and infiltration by the
malignant cells. Furthermore some may be potential therapeu-
tic targets.Conflict of interest
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